RedHill combination awarded $2.9 million NCI grant
A $2.9 million NCI grant was awarded for clinical development of RedHill’s opaganib and CAR T-cell combination in ultra-high-risk multiple myeloma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.